EQS-Adhoc: Marinomed Biotech AG: Agreement on the key terms of the issue of a secured EUR 2.5mn convertible bond

Ad hoc announcement

Marinomed Biotech AG: Agreement on the key terms of the issue of a secured EUR 2.5mn convertible bond

Korneuburg, September 1, 2025 - Marinomed Biotech AG (the "Company") announces that it has reached a basic agreement with an investor based in Germany on the key terms of an intended issue of convertible bonds to be secured by selected receivables and patents in a nominal value of EUR 2,500,000 and a term of 12 months (extendable to 24 months), which are to be subscribed exclusively by the investor (subject to the exclusion of existing shareholders' subscription rights). The convertible bond shall bear interest at 8.5%, with interest payable at maturity and not being subject to any conversion rights. The convertible bond shall provide for a conversion right into shares of the Company at a conversion price of EUR 15 per share (corresponding to a conversion right in up to 166,666 shares of the Company). The convertible bond is intended to be issued in September 2025 and is inter alia subject to the suspensive condition of the required resolutions of an extraordinary shareholders meeting of the Company to be convoked at short notice. The extraordinary shareholders meeting shall in particular resolve on the authorization of the management board to issue the convertible bond subject to the supervisory board's consent, on the exclusion of shareholders' subscription rights as well as a new conditional capital for underlying the conversion claims under the convertible bond. In the event of conversion of the convertible bond, it is intended to convert the shares from the Company's conditional capital to be resolved. Marinomed is also evaluating further financing options.

+++ End of ad-hoc announcement +++

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline. The Company develops innovative patent-protected products based on the Marinosolv® platform. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com.

For further inquiries contact:

Disclaimer 

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.